Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Prostatic Neoplasms 44Urinary Bladder Neoplasms 42Testicular Neoplasms 30Carcinoma, Transitional Cell 30Ovarian Neoplasms 28Testicular Germ Cell Tumor 16Carcinoma, Non-Small-Cell Lung 14Melanoma 11Kidney Neoplasms 11Carcinoma, Renal Cell 11Breast Neoplasms 11Wilms Tumor 10Urethral Neoplasms 10Teratoma 10Sarcoma 10Pancreatic Neoplasms 10Central Nervous System Neoplasms 10Colorectal Neoplasms 9Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Stomach Neoplasms 7Ovarian Germ Cell Cancer 7Neoplasms 7Seminoma 6Osteosarcoma 6Neuroblastoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Ureteral Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Carboplatin × Genitourinary × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡